Blephamide® Ointment
sulfacetamide 10% / prednisolone 0.2% · ophthalmic ointment
Antibiotic/Steroid
Approved uses
Steroid-responsive ocular inflammation with superficial bacterial infection or a risk of it
Approximately 1/2 inch ribbon in the conjunctival sac three or four times daily and once or twice at night; not more than 8 g initially
Chronic anterior uveitis, and corneal injury from chemical, radiation, or thermal burns or foreign body penetration
Approximately 1/2 inch ribbon in the conjunctival sac three or four times daily and once or twice at night; not more than 8 g initially
Contraindications
- Most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella
- Mycobacterial infection of the eye
- Fungal diseases of ocular structures
- Known or suspected hypersensitivity to any of the ingredients of this preparation, to other sulfonamides and to other corticosteroids (hypersensitivity to the antimicrobial component occurs at a higher rate than for other components)
Ophthalmic ointment, 10%/0.2% (sulfacetamide sodium 10%, prednisolone acetate 0.2%), 3.5 g tube
Sulfacetamide is bacteriostatic, competing with p-aminobenzoic acid to restrict the folic acid synthesis susceptible bacteria need for growth; prednisolone acetate suppresses the inflammatory response and probably delays or slows healing. The anti-infective is present because corticosteroids may inhibit the body's defense mechanism against infection, so the pairing is aimed at settings where the risk of superficial infection is high or potentially dangerous numbers of bacteria are expected.
Warnings & Precautions
- Not for injection into the eye: This is a topical ophthalmic ointment and is not for injection into the eye.
- IOP elevation and glaucoma: Prolonged corticosteroid use may produce ocular hypertension or glaucoma with optic nerve damage and defects in visual acuity and visual fields; check IOP routinely if used 10 days or longer, even though it may be difficult in children and uncooperative patients, use with caution in the presence of glaucoma, and check IOP frequently.
- Posterior subcapsular cataract: Prolonged corticosteroid use may produce it.
- Delayed healing: Steroids after cataract surgery may delay healing and increase the incidence of filtering blebs; ophthalmic ointments may also retard corneal healing.
- Secondary or masked infection: Prolonged use may suppress host response and increase the hazard of secondary ocular infection; in acute purulent conditions corticosteroids may mask infection or enhance existing infection.
- Viral infection exacerbation: Ocular corticosteroids may prolong the course and worsen the severity of many ocular viral infections including herpes simplex; herpes simplex treatment requires great caution.
- Corneal or scleral perforation: In diseases causing thinning of the cornea or sclera, perforation has occurred with topical corticosteroids.
- Severe sulfonamide reactions: Fatalities have occurred, although rarely, from Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias; sensitization may recur when a sulfonamide is readministered, irrespective of the route of administration, and if signs of hypersensitivity or other serious reaction occur, discontinue use.
- Corticosteroid cross-sensitivity: Cross-sensitivity among corticosteroids has been demonstrated.
- Acute anterior uveitis: May occur in susceptible individuals, primarily Blacks.
- Sulfonamide resistance: A significant percentage of staphylococcal isolates are completely resistant to sulfonamides; p-aminobenzoic acid present in purulent exudates competes with sulfonamides and can reduce their effectiveness.
- Mustard gas keratitis and Sjögren's keratoconjunctivitis: Topical steroids are not effective in these conditions.
- Severe dry eye: Use with caution.
- Initial prescription and renewal: The initial prescription and renewal beyond 8 g should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining; re-evaluate the patient if signs and symptoms fail to improve after two days.
- Fungal infections of the cornea: Consider this possibility after prolonged corticosteroid dosing, and take fungal cultures when appropriate.
- Persistent inflammation or pain: If inflammation or pain persists longer than 48 hours or becomes aggravated, advise the patient to discontinue use and consult a physician.
- Incompatibility with silver preparations: The ointment is incompatible with silver preparations, and local anesthetics related to p-aminobenzoic acid may antagonize the action of the sulfonamides.
- Contamination: To prevent contamination, avoid touching the tube tip to eyelids or to any other surface; use of this tube by more than one person may spread infection.
- Laboratory tests: Eyelid cultures and tests to determine the susceptibility of organisms to sulfacetamide may be indicated if signs and symptoms persist or recur in spite of the recommended course of treatment.
Common Side Effects
Corticosteroid reactions, in decreasing order of frequency, are IOP elevation with possible glaucoma and infrequent optic nerve damage, posterior subcapsular cataract, and delayed wound healing. Corticosteroids can also cause acute anterior uveitis or globe perforation, and mydriasis, loss of accommodation, and ptosis have occasionally been reported. Exact incidence figures are not available, since no denominator of treated patients is available. The antibacterial ingredient most often causes allergic sensitizations, and sulfacetamide sodium may cause local irritation. Fatalities have occurred, although rarely, due to severe sulfonamide reactions. Fungal and viral corneal infections are particularly prone to develop with long-term corticosteroid use, and secondary bacterial infection also occurs. Rare systemic hypercorticoidism has occurred after topical corticosteroid use.
Pregnancy: Category C. No adequate well-controlled studies in pregnant women dosed with corticosteroids, and no animal reproduction studies with sulfacetamide sodium. Prednisolone is teratogenic in rabbits, hamsters, and mice, and ocular application of dexamethasone, hydrocortisone and prednisolone to both eyes of pregnant mice five times daily on gestation days 10 through 13 significantly increased cleft palate in the fetuses. Systemic sulfonamides given in the third trimester may precipitate kernicterus in infants. Use only if the potential benefit justifies the potential fetal risk.
Lactation: Whether topical administration produces detectable quantities in human milk is unknown. Systemically administered corticosteroids appear in human milk and could suppress growth or interfere with endogenous corticosteroid production, and systemically administered sulfonamides can produce kernicterus in infants of lactating women; decide whether to discontinue nursing or the drug.
Safety and effectiveness in children below age 6 have not been established.